A retrospective study of 31 children presenting in the period 1976–1993 with intracranial ependymomas in the south-west region of the UK was performed. The diagnosis was confirmed by histological review and several histological variables recorded, including pleomorphism, cellularity, numbers of mitotic figures and extent of necrosis. Histological features, presentation and treatment were correlated with outcome. Eleven patients had supratentorial primaries and 20 infratentorial primaries. Seven patients had macroscopically complete resections of which 5 had supratentorial primaries. Eight patients had no other therapy apart from surgery. Six patients received craniospinal irradiation, 11 had involved-field irradiation and 14 did not have radical radiotherapy. Twelve patients received chemotherapy. Eleven patients are relapse-free at a median of 43 months. Of the 20 relapses, 19 were local and only 1 metastatic. The grade of the tumor assigned at presentation had no correlation with outcome. On histological review, the only feature that had a significant correlation (p = 0.05) with survival was tumor cellularity. There was a survival advantage for a supratentorial primary site (p = 0.04). The event-free survival was significantly longer for patients diagnosed after 1986 than before (p = 0.006). Survival was not significantly affected by radiotherapy or chemotherapy. Children who had had a macroscopically complete excision of the tumor had a 5-year survival of 69% as opposed to 47% for those who had incomplete surgery, but this difference is not significant (p = 0.13). The data suggest that: (1) the event-free survival rate has improved significantly with time; (2) there is little correlation between a variety of pathological features and outcome, and (3) failure at the primary site is the major obstacle to improved cure rates. The role of complete resection, including second-look surgery, needs further evaluation.
Background. Medulloblastoma is one of the most common intracranial tumors in children. The perception that the incidence of this tumor has declined is reinforced by a decline in enrollment to international trials for the disease. Methods. A retrospective population‐based study of children younger than 15 years whose brain tumors were reviewed histopathologically was performed in the county of Avon, in the southwest region of England from 1976 to 1991. Then, the incidence of medulloblastoma was studied in the noncontiguous southwest and northern regions of England, with a combined childhood population base of 20.0 million child years for the period 1976‐1991. Results. In Avon, 16 children with medulloblastoma presented in the period 1976–1984 and 2 in the period 1985–1991, representing a decrease in incidence from 9.6 per million per year to 1.7 per million per year. The incidence of medulloblastoma in the combined southwest and northern regions showed a significant (P = 0.006) decline from 5.5 per million per year in the period 1976–1984 to 2.8 in the period 1985–1991. Considered individually, the decline in the southwest (from 6.2 per million per year to 2.8 per million per year) was significant but that in the Northern region (from 4.7 to 2.7) was not. Conclusions. In this report, a decline in the incidence of medulloblastoma was shown. In a recent case control study, a protective effect of maternal folate, iron, and multivitamin supplementation against primitive neuroectodermal tumors, including medulloblastoma was found. The introduction of periconceptional multivitamin supplementation in the 1980s may have caused this significant decline in the incidence of medulloblastoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.